98%
921
2 minutes
20
Background: Diabetic retinopathy has a significant impact in every healthcare system. Despite that fact, there are few accurate estimates in the prevalence of DR in Brazil's different geographic regions, particularly proliferative DR and diabetic macular edema. This study aims to determine the prevalence of diabetic retinopathy in Brazil's five continental regions and its determinant factors.
Methods: This multi center, cross-sectional, observational study, conducted between August 2011 and December 2014, included patients with type 1 diabetes from the 5 Brazilian geographic regions (South, Southeast, North, Northeast and Midwest). During a clinical visit, a structured questionnaire was applied, blood sampling was collected and each patient underwent mydriatic binocular indirect ophthalmoscopy evaluation.
Results: Data was obtained from 1644 patients, aged 30.2 ± 12 years (56.1% female, 54.4% Caucasian), with a diabetes duration of 15.5 ± 9.3 years. The prevalence of diabetic retinopathy was 242 (36.1%) in the Southeast, 102 (42.9%) in the South, 183 (29.9%) in the North and Northeast and 54 (41.7%) in the Midwest. Multinomial regression showed no difference in the prevalence of non-proliferative diabetic retinopathy in each geographic region, although, prevalence of proliferative diabetic retinopathy (p = 0.022), and diabetic macular edema (p = 0.003) was higher in the Midwest. Stepwise analyses reviled duration of diabetes, level of HbA1c and hypertension as independent variables.
Conclusions: The prevalence of non proliferative diabetic retinopathy in patients with type 1 diabetes was no different between each geographic region of Brazil. The Midwest presented higher prevalence of proliferative diabetic retinopathy and diabetic macular edema. Duration of DM and glycemic control is of central importance to all. Hypertension is another fundamental factor to every region, at special in the South and Southeast. Glycemic control and patients in social and economic vulnerability deserves special attention in the North and Northeast of Brazil.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870814 | PMC |
http://dx.doi.org/10.1186/s13098-018-0319-4 | DOI Listing |
Int J Surg
September 2025
Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University.
Diabetic retinopathy (DR) remains a leading cause of preventable blindness worldwide, with the affected population projected to reach 270 million by 2045. Our study analyzed 2 434 interventional trials registered between 2007 and 2024 in the Informa Pharma Intelligence database and found that anti-VEGF agents dominate the therapeutic landscape-bevacizumab represents 24.0 % of studies, ranibizumab 15.
View Article and Find Full Text PDFClin Ophthalmol
September 2025
Internal Medicine Department, Medical Faculty, Universitas Brawijaya, Malang, Indonesia.
Purpose: To evaluate macular vessel density using clinical parameters in patients with type 2 diabetes mellitus (DM) without retinopathy.
Patients And Methods: This cross-sectional study enrolled 32 participants (63 eyes) aged 40-60 years who met the inclusion criteria. Group 1 included 32 eyes of type 2 DM, whereas the rest had no DM.
Front Pharmacol
August 2025
State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, China.
Diabetes mellitus is a metabolic disease with a high global prevalence, which affects blood vessels throughout the entire body. As the disease progresses, it often leads to complications, including diabetic retinopathy and nephropathy. Currently, in addition to traditional cellular and animal models, more and more organoid models have been used in the study of diabetes and have broad application prospects in the field of pharmacological research.
View Article and Find Full Text PDFJMIR Med Inform
September 2025
Global Health Economics Centre, Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Background: Artificial intelligence (AI) algorithms offer an effective solution to alleviate the burden of diabetic retinopathy (DR) screening in public health settings. However, there are challenges in translating diagnostic performance and its application when deployed in real-world conditions.
Objective: This study aimed to assess the technical feasibility of integration and diagnostic performance of validated DR screening (DRS) AI algorithms in real-world outpatient public health settings.
Biochem Biophys Res Commun
September 2025
Department of Ophthalmology, Hebei Medical University, NO. 361 Zhongshan East Road, Changan District, Shijiazhuang City, Hebei Province, China; Department of Ophthalmology, Hebei General Hospital, NO. 348 Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province, China. Electronic address
Diabetic retinopathy (DR) is among the most prevalent complications linked to advanced diabetes. Capillary Basement membrane (CBM) thickening is an early clinical manifestation in DR, and Laminin α 1 (LAMA1) is one of the main extracellular matrix components involved in CBM formation. Dapagliflozin (DAPA) has demonstrated efficacy in ameliorating DR.
View Article and Find Full Text PDF